9 results about "T cell response" patented technology

The present invention relates to a binding protein and use thereof, the binding protein comprising a first binding domain, a second binding domain, and a third binding domain, wherein: the first binding domain is a domain that specifically binds to a tumor-associated antigen (TAA); the second binding domain is both an auxiliary domain that specifically binds to the TAA and a domain that repolarizes the tumor microenvironment (TME) from tolerogenic to pro-inflammatory and, at the same time, specifically binds to an immune checkpoint protein, for in situ T cell priming; and the third binding domain is an effector molecule for inducing T cell response activation and in situ T cell priming in the TME.

The present invention relates to a FLT3L–flagellin hybrid adjuvant with enhanced antigen cross-presentation efficacy and a vaccine composition comprising same. The hybrid adjuvant of the present invention demonstrated significant therapeutic efficacy as an adjuvant for a therapeutic cancer vaccine in a preclinical mouse model of cervical cancer, resulting in complete tumor regression and sustained protection. In addition, the hybrid adjuvant of the present invention induced tumor-specific antigen CD8+ T cell responses and progenitor-exhausted CD8+ T cells (Tpex) due to an increase in cross-presentation by conventional type 1 dendritic cells (cDC1) in tumor-draining lymph nodes and the tumor microenvironment, and the combination of TCV having the hybrid adjuvant applied thereto and anti-PD-1 therapy significantly improves survival outcomes in anti-PD-1–resistant tumors, and thus can be advantageously applied in anticancer immunotherapy using therapeutic cancer vaccines.

This application relates to a method for detecting an antigen-specific T cell response in a whole blood or PBMC sample comprising collecting a sample, incubating the sample simultaneously with an antigen and a reporter cell line expressing at least one reporter gene that detects the presence of an antigen-specific T cell response product. It also relates to a vector for detecting an antigen-specific T cell response comprising a transcriptional response element and at least one reporter gene and the kit thereof.

Provided herein is DNA vaccine and composition comprising PD1-based TWIST1. Also provided is a method for inducing TWIST1-specific T cell response by administering a PD1-based TWIST1 vaccine. Also provided is a method for inducing TWIST1-specific T cell response by administering a PD1-based TWIST1 vaccine and an immune checkpoint inhibitor.

This disclosure relates to the field of RNA to prevent or treat multiple infectious agents. In particular, the present disclosure relates to methods and agents for vaccination against coronavirus infection and influenza virus infection and inducing effective coronavirus and influenza virus antigen-specific immune responses such as antibody and / or T cell responses.

The application discloses a LAG-3 binding molecule, which comprises a LAG-3 antibody, or an antigen binding fragment of the LAG-3 antibody, or a fusion protein containing the LAG-3 antibody, or a fusion protein containing the antigen binding fragment, or an antibody drug conjugate containing the LAG-3 antibody, or an antibody drug conjugate containing the antigen binding fragment, or a bispecific antibody containing the LAG-3 antibody or a bispecific antibody containing the antigen binding fragment. The LAG-3 binding molecule provided by the application can bind to human and monkey LAG-3, has high affinity to human LAG-3, effectively enhances T cell response, can be used for regulating T cell and antibody-mediated immune response, and has wide therapeutic uses as an immunomodulator, such as cancer, autoimmune diseases, inflammatory diseases, and infectious diseases.

The application provides a recombinant oncolytic virus, a preparation method and a use thereof, wherein the recombinant oncolytic virus is rVSV M51R mIL27, in the application, by introducing IL-27 into the oncolytic vesicular stomatitis virus, on the one hand, the oncolytic vesicular stomatitis virus can be used as a delivery carrier to continuously express IL-27 in the tumor part, improve the effective concentration of IL-27 in the tumor microenvironment, and avoid systemic toxic side effects; on the other hand, IL-27 can synergize with the immune cell death induced by the oncolytic vesicular stomatitis virus to further enhance the antigen-specific T cell response and promote the transformation of tumor-infiltrating lymphocytes from an exhausted state to an effector state. Meanwhile, IL-27 helps to reshape the tumor immune microenvironment by inhibiting the immune suppressive cell population, thereby improving the overall immune response level. Therefore, the recombinant oncolytic virus provided in the application realizes multi-dimensional immune regulation of the tumor microenvironment through virus-mediated targeted delivery and continuous expression, thereby significantly improving the anti-tumor effect of the oncolytic virus therapy.

The application discloses a system for predicting the prognosis of a liver cancer patient based on HED. The system comprises a sample data acquisition module, an HED calculation module, a tumor-related antigen peptide prediction module and a prediction result output module. The system for predicting the prognosis of a liver cancer patient based on HED can more accurately predict the prognosis of liver cancer. It is found that high HED is related to good prognosis of liver cancer, corresponding to more TAA peptide segments capable of binding to HLA-I and stronger anti-tumor T cell response, and the above principle can be applied to predict the recurrence risk of early, medium and late liver cancer patients after treatment.

This disclosure relates to the field of RNA to prevent or treat multiple infectious agents. In particular, the present disclosure relates to methods and agents for vaccination against coronavirus infection, influenza infection, and / or RSV infection and inducing effective coronavirus, influenza virus, and / or RSV antigen-specific immune responses such as antibody and / or T cell responses. Specifically, in one embodiment, the present disclosure relates to methods comprising administering to a subject (i) a bivalent RNA vaccine encoding peptides or proteins comprising epitopes of SARS-CoV-2 spike proteins (S proteins) and (ii) a tetravalent RNA vaccine encoding peptides or proteins comprising epitopes of hemagglutinin (HA), for inducing an immune response against coronavirus S proteins, in particular S proteins of SARS-CoV-2, and influenza proteins, in particular HA proteins of type A and type B influenza viruses, in the subject.